Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.
Research output: Contribution to conference › Paper
Standard Standard
Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease. / Hughes, D.; Hughes, D.A.; Bodger, K. et al.
2008. Paper presented at Welsh Health Economics Group, Swansea University, Wales, UK.
2008. Paper presented at Welsh Health Economics Group, Swansea University, Wales, UK.
Research output: Contribution to conference › Paper
HarvardHarvard
Hughes, D, Hughes, DA, Bodger, K & Kikuchi, T 2008, 'Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.', Paper presented at Welsh Health Economics Group, Swansea University, Wales, UK, 3/01/01.
APA
Hughes, D., Hughes, D. A., Bodger, K., & Kikuchi, T. (2008). Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.. Paper presented at Welsh Health Economics Group, Swansea University, Wales, UK.
CBE
Hughes D, Hughes DA, Bodger K, Kikuchi T. 2008. Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease. Paper presented at Welsh Health Economics Group, Swansea University, Wales, UK.
MLA
Hughes, D. et al. Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.. Welsh Health Economics Group, Swansea University, Wales, UK, 03 Jan 0001, Paper, 2008.
VancouverVancouver
Hughes D, Hughes DA, Bodger K, Kikuchi T. Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.. 2008. Paper presented at Welsh Health Economics Group, Swansea University, Wales, UK.
Author
RIS
TY - CONF
T1 - Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.
AU - Hughes, D.
AU - Hughes, D.A.
AU - Bodger, K.
AU - Kikuchi, T.
PY - 2008/4/1
Y1 - 2008/4/1
M3 - Paper
T2 - Welsh Health Economics Group, Swansea University, Wales, UK
Y2 - 3 January 0001
ER -